Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LAP3 | P28838 | 3/20 | 0.47 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.47 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.47 |
| ▸ | ANPEP | P15144 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4865803 | 0.96 | TSHR (0.49) | LAP3ERAP2ERAP1FOLH1ANPEP | |
| SCHEMBL1374848 | 0.90 | FOLH1 (0.59) | FOLH1 | |
| SCHEMBL1374317 | 0.86 | FOLH1 (0.57) | FOLH1TSHR | |
| SCHEMBL4869112 | 0.85 | ERAP2 (0.46) | LAP3ERAP2ERAP1FOLH1ANPEP | |
| SCHEMBL5053123 | 0.81 | FOLH1 (0.61) | FOLH1 | |
| SCHEMBL10929109 | 0.81 | CPB2 (0.55) | TSHRGRIK1 | |
| SCHEMBL14112044 | 0.80 | FOLH1 (0.56) | FOLH1 | |
| SCHEMBL10933288 | 0.78 | POLB (0.59) | LAP3ERAP2ERAP1ANPEPTSHR | |
| SCHEMBL5051214 | 0.77 | CYP1A2 (0.56) | FOLH1 | |
| SCHEMBL5053018 | 0.77 | TBXAS1 (0.55) | ERAP2ERAP1ANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7402576-B2 | Phosphinic acid analogs of glutamate | GIVAUDAN SA (CH) | 2008-07-22 | — | — | US | disclosed |
| US-7402576-B2 | Phosphinic acid analogs of glutamate | GIVAUDAN SA (CH) | 2008-07-22 | — | — | US | disclosed |
| US-7402576-B2 | Phosphinic acid analogs of glutamate | GIVAUDAN SA (CH) | 2008-07-22 | — | — | US | disclosed |
| EP-1599487-B1 | PHOSPHINIC ACID ANALOGS OF GLUTAMATE | GIVAUDAN SA (CH) | 2007-07-11 | — | — | EP | disclosed |
| US-20060052616-A1 | Phosphinic acid analogs of glutamate | GIVAUDAN SA (CH) | 2006-03-09 | — | — | US | disclosed |
| EP-1599487-A1 | PHOSPHINIC ACID ANALOGS OF GLUTAMATE | Givaudan SA (CH) | 2005-11-30 | — | — | EP | disclosed |
| WO-2004043971-A1 | PHOSPHINIC ACID ANALOGS OF GLUTAMATE | GIVAUDAN SA (CH) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052616-A1 | Phosphinic acid analogs of glutamate | GLUL, GRIA1, GRM1 | LAP3 3020/4885ERAP2 2679/4885ERAP1 2093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.